Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
100%(6 trials)

Phase Distribution

Ph phase_3
5
71%
Ph phase_2
2
29%

Phase Distribution

0

Early Stage

2

Mid Stage

5

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
5(71.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(6)

Detailed Status

Completed6
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (28.6%)
Phase 35 (71.4%)

Trials by Status

enrolling_by_invitation114%
completed686%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_3

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

NCT02077192
completedphase_3

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

NCT03764618
enrolling_by_invitationphase_3

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

NCT04138927
completedphase_3

A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

NCT02076399
completedphase_3

A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

NCT02076412
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT02077192Phase 3

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Completed
NCT03764618Phase 3

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

Completed
NCT04138927Phase 3

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Enrolling By Invitation
NCT02076399Phase 3

A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Completed
NCT02076412Phase 3

A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Completed
NCT00798096Phase 2

Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma

Completed
NCT00923481Phase 2

A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7